LP
NKTR icon

LMR Partners’s Nektar Therapeutics NKTR Stock Holding History

LMR Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.47M Buy
+48,294
New +$2.75M 0.01% 736
2022
Q2 		– Sell
-4,085
Closed -$330K – 1405
2022
Q1 		$330K Sell
4,085
-330
-7% -$48.8K ﹤0.01% 1058
2021
Q4 		$895K Buy
+4,415
New +$958K 0.01% 771
2020
Q1 		– Sell
-11,731
Closed -$3.8K – 384
2019
Q4 		$3.8K Buy
+11,731
New +$3.4M 0.01% 92
2018
Q4 		– Sell
-832
Closed -$761K – 437
2018
Q3 		$761K Sell
832
-7,875
-90% -$6.72M 0.05% 154
2018
Q2 		$6.38M Buy
+8,707
New +$10M 0.33% 74

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

LMR Partners's NKTR Position: Q1 2026 in Review

LMR Partners opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 48,294 shares worth $3.47M. The stake represents 0.01% of the portfolio and ranks #736 among its holdings. This is a return to the name: LMR Partners previously reported a position in NKTR as recently as Q1 2022.

LMR Partners first reported a position in NKTR in Q2 2018 and has held it in 6 quarters since. The position peaked at $6.38M in Q2 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • LMR Partners held 48,294 shares of Nektar Therapeutics worth $3.47M as of Q1 2026.
  • Nektar Therapeutics was a new LMR Partners position in Q1 2026.
  • Nektar Therapeutics made up 0.01% of LMR Partners's portfolio in Q1 2026, its #736 holding.
  • LMR Partners first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • LMR Partners's Nektar Therapeutics position peaked at $6.38M in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.